Abstract Details

Title Endpoint Data from Secondary Stroke Prevention Clinical Trials Is Modified by Patient Preference for Various Health Outcome States

Topic

Presentation(s)

Poster/Presentation
Number 026

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Salman Bhai, MD (IEEM)	Dr. Bhai has received personal compensation in the range of $500-$4,999 for serving as a Consultant for KabaFusion. Dr. Bhai has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Grifols. Dr. Bhai has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Bhai has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Bhai has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Bhai has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Dr. Bhai has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Bhai has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Epirium Bio. Dr. Bhai has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Taysha Gene Therapies. Dr. Bhai has received publishing royalties from a publication relating to health care.
Kerri Schoedel	No disclosure on file
Matthew A. mendelsohn, BA	No disclosure on file
Ian J. Sutton, PhD	Dr. Sutton has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Sutton has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Sutton has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.
	No disclosure on file
	No disclosure on file
	No disclosure on file